Rabeprazole controls GERD symptoms in a patient for whom treatment with lansoprazole failed: first report of "cluster GERD.".
作者信息
Oh David S, Ohning Gordon V, Pisegna Joseph R
机构信息
Veterans Administration Greater Los Angeles Healthcare System and CURE: VA/UCLA Digestive Diseases Research Center, Division of Digestive Diseases, David Geffen School of Medicine at University of California, Los Angeles, California 90073, USA.
出版信息
Dig Dis Sci. 2005 May;50(5):853-7. doi: 10.1007/s10620-005-2652-3.
Abstract
摘要
相似文献
1
Rabeprazole controls GERD symptoms in a patient for whom treatment with lansoprazole failed: first report of "cluster GERD.".
Dig Dis Sci. 2005 May;50(5):853-7. doi: 10.1007/s10620-005-2652-3.
2
Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
Clin Ther. 2001 Jul;23(7):998-1017. doi: 10.1016/s0149-2918(01)80087-4.
3
Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
Manag Care. 2002 Jul;11(7 Suppl):14-8.
4
[Pharmacogenomical aspects of gastroesophageal reflux disease].
Vestn Ross Akad Med Nauk. 2005(6):33-6.
5
Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
Drugs. 1999 Oct;58(4):725-42. doi: 10.2165/00003495-199958040-00014.
6
Review article: efficacy and safety of rabeprazole in treating gastroesophageal reflux disease.
J Gastroenterol Hepatol. 2004 Sep;19 Suppl 3:S61-8. doi: 10.1111/j.1440-1746.2004.03592.x.
7
Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Eur J Clin Pharmacol. 2004 Oct;60(8):531-9. doi: 10.1007/s00228-004-0804-6. Epub 2004 Sep 2.
8
Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole.
J Gastroenterol Hepatol. 2003 Dec;18(12):1392-8. doi: 10.1046/j.1440-1746.2003.03190.x.
9
Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Am J Gastroenterol. 2003 Dec;98(12):2616-20. doi: 10.1111/j.1572-0241.2003.08783.x.
10
Review article: relief of symptoms in gastric acid-related diseases--correlation with acid suppression in rabeprazole treatment.
Aliment Pharmacol Ther. 2004 Nov;20 Suppl 6:20-9. doi: 10.1111/j.1365-2036.2004.02162.x.
引用本文的文献
1
Real-world-evidence, prospective-observational study to evaluate safety and effectiveness of rabeprazole dual-delayed-release capsules in patients with gastroesophageal reflux disease.
World J Gastrointest Pharmacol Ther. 2025 Mar 5;16(1):103898. doi: 10.4292/wjgpt.v16.i1.103898.
本文引用的文献
1
Rabeprazole is superior to omeprazole for the inhibition of peptone meal-stimulated gastric acid secretion in Helicobacter pylori-negative subjects.
Aliment Pharmacol Ther. 2003 May 1;17(9):1109-14. doi: 10.1046/j.1365-2036.2003.01573.x.
2
The proton-pump inhibitors: similarities and differences.
Clin Ther. 2000 Mar;22(3):266-80; discussion 265. doi: 10.1016/S0149-2918(00)80032-6.
3
Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection.
Aliment Pharmacol Ther. 2000 Jun;14(6):701-8. doi: 10.1046/j.1365-2036.2000.00774.x.
4
An evidence-based appraisal of reflux disease management--the Genval Workshop Report.
Gut. 1999 Apr;44 Suppl 2(Suppl 2):S1-16. doi: 10.1136/gut.44.2008.s1.
5
Gastroesophageal reflux disease: prevalence, clinical, endoscopic and histopathological findings in 1,128 consecutive patients referred for endoscopy due to dyspeptic and reflux symptoms.
Digestion. 2000;61(1):6-13. doi: 10.1159/000007730.
6
Factors influencing compliance in long-term proton pump inhibitor therapy in general practice.
Br J Gen Pract. 1999 Jun;49(443):463-4.
7
Review article: the pharmacology of rabeprazole.
Aliment Pharmacol Ther. 1999 Aug;13 Suppl 3:3-10. doi: 10.1046/j.1365-2036.1999.00019.x.
8
Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease.
Aliment Pharmacol Ther. 1997 Oct;11(5):973-80. doi: 10.1046/j.1365-2036.1997.00244.x.
9
Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.
J Biol Chem. 1997 Sep 5;272(36):22438-46. doi: 10.1074/jbc.272.36.22438.
10
Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux esophagitis.
Dig Dis Sci. 1993 Dec;38(12):2287-93. doi: 10.1007/BF01299910.
Zotero 插件